Once daily ceftriaxone and amikacin for outpatient treatment of neutropenic fever in children with acute lymphoblastic leukaemia

HAEMA

Volumn 6, Issue 4, 2003, Pages 501-506

  Abbas, Adil A H ^a   Felimban, Sami K ^a   Cittana, Basheer A ^a   Yousef, Abdulmotalib A ^a   Fayea, Najwa Y ^a   Khattab, Taha M ^a   Chedid, Faris D ^a   Fryer, Christopher J H ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Amikacin; Ceftriaxone; Febrile neutropenia; Outpatient treatment

Indexed keywords

AMIKACIN; CEFTRIAXONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD CULTURE; CHILD; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; REMISSION; SEPSIS; SINGLE DRUG DOSE; TREATMENT FAILURE;

EID: 0242330675     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Mustafa MM, Aquino VM, Pappo A Tsaczewski I, Buchanan GR. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bactremia. J Pediatr 1996; 128: 847-849.
2. Mullen CA, Petropoulos D, Roberts WM et al. Outpatient treatment of fever and neutropenia for low risk pediatric patients. Cancer 1999; 86: 126-134.
3. Malik I.A. Outpatient management of febrile neutropenia in indigent paediatric patients. Ann Acad Med Singapore 1997; 26: 742-746.
4. Preis S, Gobel U, Jurgens H. Outpatient treatment with ceftriaxone alone or in combination with teicoplanin in febrile neutropenic children and adolescents with cancer. J Pediatr 1997; 130: 500-501.
5. Kern WV, Cometta A, De Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341: 312-318.
6. Shemesh E. Yaniv I, Drucker M et al. Home intravenous antibiotic treatment for febrile episodes in immuno-compromised pediatric patients. Med Pediatr Oncol 1998; 30: 95-100.
7. Klaassen RJ, Goodman TR, Pham P, Doyle JJ. "Low risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-1019.
8. Paganini H, Rodriguez-Brieshcke T, Zubizarreta P et al. Oral ciprofloxacin in the management of children with cancer with lower risk febril neutropenia. Cancer 2001; 91: 1563-1567.
9. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committtee for the International Collaboration on Antimicrobial Treatment for Febrile Neutropenia in Children. Pediatr Infect Dis 1997; 16: 346-353.
10. Hughes WT, Armstrong D, Bodey GP et al. 1997 guide-lines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551-73.
11. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bactremia. Eur J Clin Microbiol Infect Dis 1999; 18: 539-544.
12. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram negative bacteria in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987; 317: 1692-1698.
13. Daw MA, Falkiner RF. Prevention of gram negative infections in neutropenic cancer patients. Saudi Med J 1994; 15: 196-203.
14. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991; 163: 951-958.
15. Rubin M, Hathron JW, Marshall D et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988; 108: 30-35.
16. Shenep J, Hughes WT, Robertson PK et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-calvulanate and amikacin in the empirical treatment of febrile neutropenic children with cancer. N Engl J Med 1988; 319: 1053-1058.
17. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemotherapy 1996; 37: 209-222.